Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

Discover 10 causes of nasal breathing difficulties from deviated septum to spray addiction, plus effective solutions for ...

As flowers bloom and temperatures climb, spring brings in allergy season for many. When sneezing, itchy eyes or sinus ...

could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been shown to reduce symptoms. Sanofi ...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Blood basophils among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) may indicate the degree of inflammation, according to findings published in the European Archives of ...

Most vaccines -- and boosters -- are injected directly into muscle tissue, usually in the upper arm, to kickstart the body's immune system in the fight against disease. But for respiratory diseases ...

Most vaccines — and boosters — are injected directly into muscle tissue, usually in the upper arm, to kickstart the body's immune system in the fight against disease.